Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free KRTX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Karuna Therapeutics (KRTX) Competitors

Karuna Therapeutics logo
Compare

KRTX vs. MANE, KLRA, GMTX, MOR, and ZYME

Should you be buying Karuna Therapeutics stock or one of its competitors? The main competitors of Karuna Therapeutics include MANE (MANE), Kailera Therapeutics (KLRA), Gemini Therapeutics (GMTX), MorphoSys (MOR), and Zymeworks (ZYME).

How does Karuna Therapeutics compare to MANE?

Karuna Therapeutics (NASDAQ:KRTX) and MANE (NYSE:MANE) are both pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

MANE has a consensus target price of $83.33, indicating a potential downside of 24.37%. Given MANE's stronger consensus rating and higher possible upside, analysts plainly believe MANE is more favorable than Karuna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karuna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MANE
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, MANE had 5 more articles in the media than Karuna Therapeutics. MarketBeat recorded 5 mentions for MANE and 0 mentions for Karuna Therapeutics. MANE's average media sentiment score of 1.45 beat Karuna Therapeutics' score of 0.00 indicating that MANE is being referred to more favorably in the news media.

Company Overall Sentiment
Karuna Therapeutics Neutral
MANE Positive

MANE has lower revenue, but higher earnings than Karuna Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna Therapeutics$654K19,239.07-$433.68M-$11.72N/A
MANEN/AN/AN/AN/AN/A

MANE's return on equity of 0.00% beat Karuna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Karuna TherapeuticsN/A -31.63% -30.38%
MANE N/A N/A N/A

Summary

MANE beats Karuna Therapeutics on 7 of the 8 factors compared between the two stocks.

How does Karuna Therapeutics compare to Kailera Therapeutics?

Karuna Therapeutics (NASDAQ:KRTX) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Kailera Therapeutics' return on equity of 0.00% beat Karuna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Karuna TherapeuticsN/A -31.63% -30.38%
Kailera Therapeutics N/A N/A N/A

Kailera Therapeutics has lower revenue, but higher earnings than Karuna Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna Therapeutics$654K19,239.07-$433.68M-$11.72N/A
Kailera TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Kailera Therapeutics had 2 more articles in the media than Karuna Therapeutics. MarketBeat recorded 2 mentions for Kailera Therapeutics and 0 mentions for Karuna Therapeutics. Karuna Therapeutics' average media sentiment score of 0.00 equaled Kailera Therapeutics'average media sentiment score.

Company Overall Sentiment
Karuna Therapeutics Neutral
Kailera Therapeutics Neutral

Summary

Kailera Therapeutics beats Karuna Therapeutics on 3 of the 4 factors compared between the two stocks.

How does Karuna Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Gemini Therapeutics has higher earnings, but lower revenue than Karuna Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Karuna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A
Karuna Therapeutics$654K19,239.07-$433.68M-$11.72N/A

In the previous week, Gemini Therapeutics had 1 more articles in the media than Karuna Therapeutics. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Karuna Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 equaled Karuna Therapeutics'average media sentiment score.

Company Overall Sentiment
Gemini Therapeutics Neutral
Karuna Therapeutics Neutral

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Karuna Therapeutics' return on equity of -31.63% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Karuna Therapeutics N/A -31.63%-30.38%

75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 13.2% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Karuna Therapeutics beats Gemini Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Karuna Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Karuna Therapeutics'average media sentiment score.

Company Overall Sentiment
MorphoSys Neutral
Karuna Therapeutics Neutral

MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Karuna Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Karuna Therapeutics' return on equity of -31.63% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Karuna Therapeutics N/A -31.63%-30.38%

MorphoSys has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Karuna Therapeutics$654K19,239.07-$433.68M-$11.72N/A

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 13.2% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

MorphoSys beats Karuna Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Karuna Therapeutics compare to Zymeworks?

Karuna Therapeutics (NASDAQ:KRTX) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Zymeworks has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna Therapeutics$654K19,239.07-$433.68M-$11.72N/A
Zymeworks$105.96M18.44-$81.13M-$1.08N/A

Karuna Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -76.56%. Zymeworks' return on equity of -26.00% beat Karuna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Karuna TherapeuticsN/A -31.63% -30.38%
Zymeworks -76.56%-26.00%-20.57%

Zymeworks has a consensus target price of $37.89, indicating a potential upside of 43.03%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Karuna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karuna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Zymeworks
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

92.9% of Zymeworks shares are owned by institutional investors. 13.2% of Karuna Therapeutics shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Zymeworks had 3 more articles in the media than Karuna Therapeutics. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Karuna Therapeutics. Zymeworks' average media sentiment score of 0.45 beat Karuna Therapeutics' score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.

Company Overall Sentiment
Karuna Therapeutics Neutral
Zymeworks Neutral

Karuna Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Summary

Zymeworks beats Karuna Therapeutics on 15 of the 17 factors compared between the two stocks.

Get Karuna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRTX vs. The Competition

Export
MetricKaruna TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.58B$904.84M$6.22B$12.12B
Dividend YieldN/A4.84%2.74%5.26%
P/E Ratio-28.141.7428.5627.24
Price / Sales19,239.07119.02534.6283.35
Price / CashN/A20.0743.3554.56
Price / Book9.927.669.926.83
Net Income-$433.68M-$4.80M$3.54B$333.00M

Karuna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRTX
Karuna Therapeutics
N/A$329.83
flat		N/AN/A$12.58B$654KN/A339
MANE
MANE
N/A$102.60
-3.7%		$83.33
-18.8%		N/A$3.82BN/AN/A19
KLRA
Kailera Therapeutics
N/A$24.94
+0.7%		N/AN/A$3.08BN/AN/A145
GMTX
Gemini Therapeutics
N/A$67.26
-2.3%		N/A+39.1%$2.91BN/AN/A30
MOR
MorphoSys
N/A$18.96
flat		N/AN/A$2.86B$238.28MN/A730

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KRTX) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel